Leland Metheny

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Leland Metheny sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 3 currently recruiting early-phase tilt upper quartile by trial count

Leland Metheny: 3 sponsored US clinical trials, 3 recruiting.

Leland Metheny sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelodysplastic Syndrome Other, with 1 trials.

Upper-quartile sponsor footprint

Leland Metheny sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Leland Metheny pipeline

3 recruiting of 3 indexed (100% open).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Myelodysplastic Syndrome Other (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Leland Metheny: open-pipeline peers nationwide

Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Leland Metheny sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Leland Metheny10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Leland Metheny sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Leland Metheny sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Leland Metheny page

3 registered trials is a research-attention snapshot, not an endorsement of Leland Metheny or any single study.

  • 3 of Leland Metheny's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Myelodysplastic Syndrome Other is the condition Leland Metheny studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelodysplastic Syndrome Other trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Leland Metheny pipeline card: 3 registered trials from official public datasets.Report a data error.